Last updated: May 28, 2026
Sodium Oxybate Drug Suppliers: Who Manufactures, Supplies, and Licenses the Market
Executive summary: Sodium oxybate supply in the US is concentrated around a small set of manufacturers tied to key brands and distribution channels. In the near term, availability risk is driven less by active ingredient scarcity and more by (1) control of regulated manufacturing sites, (2) FDA-controlled REMS-adjacent logistics for gamma-hydroxybutyrate (GHB) medicines, and (3) batch release/lot qualification tied to finished product specs and controlled-substance handling.
Who supplies sodium oxybate (GHB) in the US market?
Answer: Sodium oxybate is supplied in the US through manufacturers of the finished, FDA-approved product and through finished-goods distributors, with active ingredient supply closely controlled by the same sponsor-linked supply chain.
What brand-linked finished product suppliers exist for sodium oxybate?
The sodium oxybate market is built around FDA-approved sodium oxybate formulations for:
- Narcolepsy (cataplexy and excessive daytime sleepiness): brand Xyrem
- Idiopathic sleepiness spectrum and related indications depend on product history and approvals; current commercial reality centers on the Xyrem franchise and later sodium oxybate product formats.
Supplier structure typically looks like this:
- Finished product manufacturer (site-level): produces drug product (DP) under NDA/BLA control
- Active ingredient or key intermediate supplier: supplies sodium oxybate precursor chemistry or drug substance (DS) to DP manufacturer
- Labeler/distributor: handles US distribution and controlled-substance logistics, including wholesale distribution partners
How do controlled-substance controls affect sodium oxybate supply?
Sodium oxybate is a regulated GHB medicine. Supply is constrained by:
- regulated manufacturing approvals at DP/DS sites
- controlled substance handling and storage
- lot release and distribution documentation aligned to DEA and FDA requirements
(These controls can limit alternate-site manufacturing switching even when technical feasibility exists.)
What companies manufacture sodium oxybate drug product and drug substance?
Answer: Finished product supply is performed by NDA-holding or sponsor-linked manufacturers, while DS supply is often from a small set of chemistry providers or captive DS supply chains used by those sponsors.
Drug product manufacturing: what is typically visible in public sources?
For US prescription GHB products, the market typically shows:
- NDA sponsor labeler (the entity responsible for FDA regulatory submissions)
- Contract manufacturing organization (CMO) or in-house DP site listed in FDA databases and commercial listings
Drug substance sourcing: how concentrated is it?
Drug substance supply for sodium oxybate is frequently concentrated due to:
- chemistry complexity and impurity control
- need for validated conversion steps into the controlled sodium oxybate bulk
- tight coupling between DS source qualification and DP specs
What are the main sodium oxybate suppliers behind Xyrem?
Answer: Xyrem supply ties to the Xyrem NDA sponsor and its qualified manufacturing sites, with secondary distribution through major wholesalers.
Who is the NDA sponsor and labeler for Xyrem?
Public FDA-facing records tie Xyrem’s regulatory responsibility to its brand sponsor. The “supplier” in practice is the labeler plus its contract and in-house DP manufacturing sites.
How does distribution work for sodium oxybate finished goods?
Distribution usually involves:
- controlled-substance wholesale distributors
- distribution hubs supporting REMS-like logistics controls (where applicable to the program structure)
Are there sodium oxybate generic or authorized-supply suppliers?
Answer: Authorized supply depends on whether any entrants have FDA approval for sodium oxybate products (or authorized generics). Absent approved entrants, supply remains dominated by the originator brand sponsor’s qualified manufacturers.
How do approval pathways change supplier risk?
If an entrant is approved, supplier risk shifts from sponsor-linked manufacturing to:
- entrant’s DP/DS supply chain qualification
- new-site batch release control
- controlled substance distribution partnerships
What supplier risks affect sodium oxybate availability?
Answer: Availability risk is driven primarily by manufacturing site qualification and regulated handling constraints, not by demand alone.
Key operational risk drivers
- batch-to-batch chemistry and impurity consistency for DS
- tight control of DP dissolution, potency, and uniformity specs
- lot release delays if impurities or analytical deviations occur
- controlled substance storage and transport capacity
What triggers the biggest supply interruptions?
- DP site capacity limits
- DS supply qualification issues
- quality system investigations that pause batch release
- regulatory enforcement actions at manufacturing sites
How do sodium oxybate suppliers compare to suppliers of other GHB medicines?
Answer: The supplier model is similar across GHB medicines: a small number of qualified manufacturers, with distribution handled by controlled-substance logistics partners.
What differs by product format?
If a product format differs in dosing presentation or delivery system, the DP manufacturing step can shift, changing the actual DP supplier even when DS sourcing is stable.
What patent or exclusivity status impacts sodium oxybate supply licensing?
Answer: Current supply for originator sodium oxybate formulations is protected by composition/formulation and method-of-use intellectual property and by exclusivity protections where applicable. That reduces the feasibility of generic or authorized-supply entrants.
How do exclusivity and IP affect supplier switching?
- sponsor-linked manufacturing is maintained to preserve authorized labeling and supply continuity
- alternative manufacturing sites require extensive tech transfer and regulatory alignment
- generic entry, if feasible, still must qualify controlled substance distribution and product specs
What does the regulatory status imply for supplier qualification?
Answer: FDA approval ties product specs and labeling to the manufacturing chain. Supplier qualification is not just technical. It includes:
- validated manufacturing process
- stability and shelf-life verification
- analytical method validation for the final product
- batch release controls tied to the approved application
Key Takeaways
- Sodium oxybate supply is concentrated around sponsor-linked qualified manufacturers for FDA-approved finished products and their DS supply chains.
- Availability risk is mainly operational and regulatory: manufacturing site qualification, batch release controls, and controlled-substance logistics capacity.
- Supplier diversification depends on whether additional FDA-approved sodium oxybate products exist and whether their manufacturing sites are already qualified for DP and DS.
FAQs
- Which wholesalers distribute sodium oxybate in the US?
- Who manufactures sodium oxybate drug product at contract manufacturing sites?
- Do sodium oxybate generics have their own qualified drug substance suppliers?
- What quality attributes constrain sodium oxybate batch release most often?
- What typically causes sodium oxybate supply shortages: DS or DP capacity?
References (APA)
- FDA. (n.d.). Drugs@FDA database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- Orange Book. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- DEA. (n.d.). Controlled substances resources and manufacturing/handling requirements. U.S. Drug Enforcement Administration. https://www.dea.gov/
